Cat. No.: HY-101392

Harmane

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

Harmane is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC₅₀ = 30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF).

For research use only. We do not sell to patients.

Purity: 99.91%
CAS No.: 486-84-0
Formula: C₁₂H₁₀N₂
Molecular Weight:182.23

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Harmane Chemical Structure

CAS No.: 486-84-0

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[2]^[3]

I1-Imidazoline receptor

30 nM (IC₅₀)

hMAO-A

0.5 μM (IC₅₀)

MAO-B

5 μM (IC₅₀)

α2-adrenergic receptor

18 μM (IC₅₀)

nAChR

24 μM (IC₅₀)

benzodiazepine receptor

7 nM (IC₅₀)

Opioid receptor

2.8 μM (IC₅₀)

Loperamide

163 μM (IC₅₀)

Serotonin

101 μM (IC₅₀)

All Monoamine Oxidase Isoforms :

MAO-A
MAO-B

All Adrenergic Receptor Isoforms :

All Opioid Receptor Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
1A9	ED₅₀	6.1 μg/mL Compound: 2	In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line	[PMID: 10612592]
A549	ED₅₀	9.3 μg/mL Compound: 2	In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line	[PMID: 10612592]
A549	IC₅₀	>100 μM Compound: 5	Antiproliferative activity against human A549 cells after 24 hrs by MTT assay Antiproliferative activity against human A549 cells after 24 hrs by MTT assay	10.1039/C5MD00581G
Bel-7402	IC₅₀	151 μM Compound: 5	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 18952426]
BGC-823	IC₅₀	215 μM Compound: 5	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 18952426]
CAKI-1	ED₅₀	8 μg/mL Compound: 2	In vitro cytotoxic activity was determined against renal cancer (CAKI-1) cell line In vitro cytotoxic activity was determined against renal cancer (CAKI-1) cell line	[PMID: 10612592]
H9	EC₅₀	10.7 μM Compound: 5	Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication	[PMID: 11473435]
H9	IC₅₀	111.5 μM Compound: 5	Cytotoxicity against human H9 cells Cytotoxicity against human H9 cells	[PMID: 11473435]
HEL	ED₅₀	9.8 μg/mL Compound: 2	In vitro cytotoxic activity was determined against embryonic lung fibroblast (HEL) cell line In vitro cytotoxic activity was determined against embryonic lung fibroblast (HEL) cell line	[PMID: 10612592]
HeLa	IC₅₀	>100 μM Compound: 5	Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay	10.1039/C5MD00581G
HeLa	IC₅₀	186 μM Compound: 5	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 18952426]
HepG2	IC₅₀	115 μM Compound: 5	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 18952426]
HL-60	IC₅₀	>10 μM Compound: 18	Antiproliferative activity against human HL60 cells by tryphan blue assay Antiproliferative activity against human HL60 cells by tryphan blue assay	[PMID: 28128938]
HL-60	IC₅₀	>100 μM Compound: 5	Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay	10.1039/C5MD00581G
KB	ED₅₀	15 μg/mL Compound: 2	In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-CPT (pleotrophic mechanism including level of topoisomerase I) In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-CPT (pleotrophic mechanism including level of topoisomerase I)	[PMID: 10612592]
KB	ED₅₀	16.5 μg/mL Compound: 2	In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-7d (pleotrophic resistance including MRP multidrug resistant protein) In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-7d (pleotrophic resistance including MRP multidrug resistant protein)	[PMID: 10612592]
KB	ED₅₀	17.5 μg/mL Compound: 2	In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-VIN (expressing P-glycoprotein) In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-VIN (expressing P-glycoprotein)	[PMID: 10612592]
KB	ED₅₀	8.9 μg/mL Compound: 2	In vitro cytotoxic activity was determined against epidermoid carcinoma of the nasopharynx (KB) cell line In vitro cytotoxic activity was determined against epidermoid carcinoma of the nasopharynx (KB) cell line	[PMID: 10612592]
MCF7	ED₅₀	19 μg/mL Compound: 2	In vitro cytotoxic activity against MCF-7 (human breast cancer) cell line. In vitro cytotoxic activity against MCF-7 (human breast cancer) cell line.	[PMID: 10612592]
MCF7	IC₅₀	>100 μM Compound: 5	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	10.1039/C5MD00581G
P388	IC₅₀	>12500 ng/mL Compound: Table S4, R1C1	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 19220033]
P388	IC₅₀	25000 ng/mL Compound: 3	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 1791472]
PC-3	IC₅₀	>10 μM Compound: 18	Antiproliferative activity against human PC3 cells by MTT assay Antiproliferative activity against human PC3 cells by MTT assay	[PMID: 28128938]
Platelet	IC₅₀	>130 μM Compound: Harmane	Antiplatelet aggregation activity against collagen-induced platelet Antiplatelet aggregation activity against collagen-induced platelet	[PMID: 20329729]
Platelet	IC₅₀	130 μM Compound: Harmane	Antiplatelet activity in rabbit platelets assessed as inhibition of collagen-induced platelet aggregation Antiplatelet activity in rabbit platelets assessed as inhibition of collagen-induced platelet aggregation	[PMID: 21983333]
SGC-7901	IC₅₀	>10 μM Compound: 18	Antiproliferative activity against human SGC7901 cells by MTT assay Antiproliferative activity against human SGC7901 cells by MTT assay	[PMID: 28128938]
SGC-7901	IC₅₀	>100 μM Compound: 5	Antiproliferative activity against human SGC7901 cells after 24 hrs by MTT assay Antiproliferative activity against human SGC7901 cells after 24 hrs by MTT assay	10.1039/C5MD00581G
SK-MEL-2	ED₅₀	>20 μg/mL Compound: 2	In vitro cytotoxic activity was determined against melanoma cancer (SK-MEL-2) cell line In vitro cytotoxic activity was determined against melanoma cancer (SK-MEL-2) cell line	[PMID: 10612592]
THP-1	IC₅₀	121 μM Compound: 34	Cytotoxicity in human THP1 cells Cytotoxicity in human THP1 cells	[PMID: 19781948]
U-87MG ATCC	ED₅₀	19 μg/mL Compound: 2	In vitro cytotoxic activity against U-87-MG (glioblastoma) cell line. In vitro cytotoxic activity against U-87-MG (glioblastoma) cell line.	[PMID: 10612592]

In Vitro

Harmane also inhibits haloperidol and serotonin, with IC₅₀ values of 163 μM and 101 μM, respectively^[1].
The IC₅₀ of Harmane for benzodiazepine receptor flunitrazepam is 7 μM, the IC₅₀ for the opioid receptor is 2.8 μM, and in the presence of 50 mM sodium ions, the IC₅₀ for the opioid receptor is 42 μM, and the IC₅₀ for spiropyrinol and serotonin is 163, 101 μM^[1].
The IC₅₀ of Harmane for I1 imidazoline receptor is 30 nM), and the IC₅₀ for α2-adrenergic receptor is 18 μM^[2].
Harmane (1 μM) increases the mutagenicity of AAF to Salmonella typhimurium TA98 by three times in the presence of an S-9 mixture (containing 4 μM NADH and NADPH per ml but no NADP); in the absence of S-9, it increases the mutagenicity of N-acetyloxy AAF by 2.5 times^[4].
Harmane (5-25 μM, 0-72 h) reduced the dopamine content in PC12 cells (IC₅₀ is 21.2 μM) in a concentration-dependent manner and could reduce the dopamine content induces by L-DOPA^[6].
Harmane (20 μM, 0-72 h) inhibits the activity of tyrosine hydroxylase (TH) in PC12 cells at 24 h and restores it to normal levels at 72 h; it inhibits the expression of TH mRNA at 6 h and restores it at 48 h^[6].
Harmane (20μM, 30min) reduces the intracellular cyclic AMP level and intracellular calcium ion concentration in PC12 cells^[6].
Harmane (80-150μM, 24-48h) exhibits cytotoxicity and induces cell death^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[6]

Cell Line:

PC12
Concentration:

80-150 μM; 20, 100, 150 μM
Incubation Time:

24, 48 h
Result:

Showed cytotoxicity, and cell apoptosis was observed after 48 h of treatment with 150 μM. Concentrations higher than 150 μM could induce apoptotic cell death.
Had stronger cell viability than L-DOPA alone.

Real Time qPCR^[6]

Cell Line:

PC12
Concentration:

10-30 μM
Incubation Time:

0-72 h
Result:

Inhibited the increase in dopamine content induced by L-DOPA.
Reduced dopamine content, tyrosine hydroxylase activity and mRNA at 6 h, which was maintained for 48 h and gradually recovered at 72 h.

In Vivo

Harman (0-12.5mg/kg, i.v., single dose) has an ED₅₀ of 3.6 mg/kg for convulsant activity in rats. Its anticonvulsant effect lasts for a short time and delays the reaction time to pain^[1].
Harman (0.01-1 nM, injected into rostralventrolateral medulla, single dose) caused a decrease in blood pressure in rats^[2].
Harman (2.5-10 mg/kg, i.p., single dose) had anxiolytic and antidepressant effects in rats^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female Wistar rats^[1]
Dosage:

0, 3.125, 6.25 mg/kg, single dose; 0, 1.56, 3.125, 6 25, 12.5 mg/kg, single dose; 0, 1.56, 3.125, 6.25 mg/kg, single dose
Administration:

Intravenous injection (i.v.)
Result:

Delayed apamorphine-induced licking.
Increased body temperature in rats, reaching the highest value in 25 minutes. 3.125 mg/kg or above caused hypothermia in a dose-dependent manner. Body temperature returned to the control level 100 minutes after injection of 3.125 or 6.25 mg/kg.
Prolonged the reaction time to nociception. At 3.125 mg/kg, a delay in reaction could be detected in 20 minutes.

Animal Model:

β-carbon alkali-induced hypotension in rats^[2]
Dosage:

0.01-1 nM
Administration:

Injection into RVLM (rostralventrolateral medulla)
Result:

Caused a dose-dependent decrease in mean arterial pressure (MAP) without significant changes in heart rate (HR). Phaloxan could reverse the decrease in MAP.

Animal Model:

Male adult Sprague-Dawley rats^[5]
Dosage:

2.5, 5.0, 10 mg/kg
Administration:

Intraperitoneal injection (i.p.)
Result:

Reduced the immobility time in the swimming test and increased the time in the open arms in the maze test dose-dependently.

Chemical Information

CAS No. 486-84-0
Appearance Solid
Molecular Weight 182.23
Formula C₁₂H₁₀N₂
Color White to yellow
SMILES

CC1=NC=CC2=C1NC3=C2C=CC=C3
Structure Classification
- Alkaloids
- Pyridine Alkaloids
- Alkaloids
- Indole Alkaloids
Initial Source
- Plants
- other families
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (2)

All

Sort by:

Journal Impact Factor

mSystems

Harmane induces apoptosis through RRM2B and suppresses colorectal cancer progression. [Abstract]

2026 Jun 9:e0170425. PMID: 42262096
Front Mol Neurosci

Harmane Potentiates Nicotine Reinforcement Through MAO-A Inhibition at the Dose Related to Cigarette Smoking. [Abstract]

2022 Jun 27;15:925272. PMID: 35832393

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (548.77 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.4877 mL

27.4385 mL

54.8769 mL

5 mM

1.0975 mL

5.4877 mL

10.9754 mL

10 mM

0.5488 mL

2.7438 mL

5.4877 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (13.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (13.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (13.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (291 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. W E Müller, et al. On the neuropharmacology of harmane and other beta-carbolines. Pharmacol Biochem Behav. 1981 May;14(5):693-9. [Content Brief]

[2]. Musgrave IF, et, al. Harmane produces hypotension following microinjection into the RVLM: possible role of I(1)-imidazoline receptors. Br J Pharmacol. 2000 Mar;129(6):1057-9. [Content Brief]

[3]. Glover V, et, al. β-Carbolines as selective monoamine oxidase inhibitors:In vivo implications [Content Brief]

[4]. Umezawa K, et, al. Comutagenic effect of norharman and harman with 2-acetylaminofluorene derivatives. Proc Natl Acad Sci U S A. 1978 Feb;75(2):928-30. [Content Brief]

[5]. E D Louis, et al. Harmane induces anxiolysis and antidepressant-like effects in rats. Ann N Y Acad Sci. 2005 Aug 9;65(3):391-6. [Content Brief]

[6]. Yoo Jung Yang, et al. Effects of harman and norharman on dopamine biosynthesis and L-DOPA-induced cytotoxicity in PC12 cells. Eur J Pharmacol. 2008 Jun 10;587(1-3):57-64. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	5.4877 mL	27.4385 mL	54.8769 mL	137.1923 mL
	5 mM	1.0975 mL	5.4877 mL	10.9754 mL	27.4385 mL
	10 mM	0.5488 mL	2.7438 mL	5.4877 mL	13.7192 mL
	15 mM	0.3658 mL	1.8292 mL	3.6585 mL	9.1462 mL
	20 mM	0.2744 mL	1.3719 mL	2.7438 mL	6.8596 mL
	25 mM	0.2195 mL	1.0975 mL	2.1951 mL	5.4877 mL
	30 mM	0.1829 mL	0.9146 mL	1.8292 mL	4.5731 mL
	40 mM	0.1372 mL	0.6860 mL	1.3719 mL	3.4298 mL
	50 mM	0.1098 mL	0.5488 mL	1.0975 mL	2.7438 mL
	60 mM	0.0915 mL	0.4573 mL	0.9146 mL	2.2865 mL
	80 mM	0.0686 mL	0.3430 mL	0.6860 mL	1.7149 mL
	100 mM	0.0549 mL	0.2744 mL	0.5488 mL	1.3719 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Harmane

Anti-Infection Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Neuronal Signaling Compound Library

Natural Product Library

Reprogramming Compound Library

Medicine Food Homology Compound Library

Neurotransmitter Receptor Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Alzheimer's Disease Compound Library

Alkaloids Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Mitochondria-Targeted Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

GABA Receptor Compound Library

Human Metabolite Library

Heterocyclic Compound Library

Pain-Related Compound Library

Antihypertensive Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Ion Channel Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

RO5 Drug-like Natural Product Library

Flavor Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Harmane

All Monoamine Oxidase Isoforms

All Adrenergic Receptor Isoforms

All Opioid Receptor Isoforms

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Harmane Related Classifications

HY-101392 Related Classifications